BioCentury | Aug 11, 2014
Regulation

LDT blurred Lines

...SIX:ROG; OTCQX:RHHBY) cobas EGFR Mutation Test Xalkori crizotinib from Pfizer Inc. (NYSE:PFE) Abbott Laboratories (NYSE:ABT) Vysis...
BioCentury | Dec 10, 2012
Company News

BioView, Abbott deal

...expanding approval of its Duet Automated Scanner to include automated imaging and analysis of Abbott's Vysis...
...imaging and analysis of Abbott's Vysis Path Vysion HER-2 DNA Probe Kit. Abbott markets the Vysis...
...with Xalkori crizotinib, which Pfizer Inc. (NYSE:PFE, New York, N.Y.) markets to treat NSCLC. Abbott's Vysis...
BioCentury | Nov 12, 2012
Company News

Response Genetics sales and marketing update

...NYSE:PFE, New York, N.Y.) markets Xalkori, while Abbott Laboratories (NYSE:ABT, Abbott Park, Ill.) markets the Vysis...
BioCentury | Nov 5, 2012
Company News

Abbott sales and marketing update

...Abbott launched the Vysis ALK Break Apart FISH Probe test kit in the EU as a...
BioCentury | Jul 9, 2012
Company News

Response Genetics sales and marketing update

...NYSE:PFE, New York, N.Y.) markets Xalkori while Abbott Laboratories (NYSE:ABT, Abbott Park, Ill.) markets the Vysis...
BioCentury | Feb 16, 2012
Cover Story

Strategies against Xalkori resistance

...NSCLC will be important during treatment with the drug. Xalkori was approved concurrently with the Vysis...
BioCentury | Oct 31, 2011
Clinical News

Vysis EGR1 FISH Probe Kit regulatory update

...FDA granted 510(k) clearance to Abbott's Vysis EGR1 FISH Probe Kit to aid in the prognosis...
...associated with an unfavorable prognosis in AML patients. Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Product: Vysis...
BioCentury | Sep 19, 2011
Product Development

Xalkori's footsteps

...variants, targets the EML4-ALK translocation. At the same time, FDA also approved the companion diagnostic Vysis...
BioCentury | Sep 5, 2011
Company News

Abbott, Pfizer sales and marketing update

...weeks in Xalkori's pivotal trials, the total treatment cost would be about $52,800-$76,800. The companion Vysis...
BioCentury | Aug 31, 2011
Company News

Pfizer, Abbott set price for Xalkori, companion test

...weeks in Xalkori's pivotal trials, the total treatment cost would be about $52,800-$76,800. The companion Vysis...
Items per page:
1 - 10 of 142
BioCentury | Aug 11, 2014
Regulation

LDT blurred Lines

...SIX:ROG; OTCQX:RHHBY) cobas EGFR Mutation Test Xalkori crizotinib from Pfizer Inc. (NYSE:PFE) Abbott Laboratories (NYSE:ABT) Vysis...
BioCentury | Dec 10, 2012
Company News

BioView, Abbott deal

...expanding approval of its Duet Automated Scanner to include automated imaging and analysis of Abbott's Vysis...
...imaging and analysis of Abbott's Vysis Path Vysion HER-2 DNA Probe Kit. Abbott markets the Vysis...
...with Xalkori crizotinib, which Pfizer Inc. (NYSE:PFE, New York, N.Y.) markets to treat NSCLC. Abbott's Vysis...
BioCentury | Nov 12, 2012
Company News

Response Genetics sales and marketing update

...NYSE:PFE, New York, N.Y.) markets Xalkori, while Abbott Laboratories (NYSE:ABT, Abbott Park, Ill.) markets the Vysis...
BioCentury | Nov 5, 2012
Company News

Abbott sales and marketing update

...Abbott launched the Vysis ALK Break Apart FISH Probe test kit in the EU as a...
BioCentury | Jul 9, 2012
Company News

Response Genetics sales and marketing update

...NYSE:PFE, New York, N.Y.) markets Xalkori while Abbott Laboratories (NYSE:ABT, Abbott Park, Ill.) markets the Vysis...
BioCentury | Feb 16, 2012
Cover Story

Strategies against Xalkori resistance

...NSCLC will be important during treatment with the drug. Xalkori was approved concurrently with the Vysis...
BioCentury | Oct 31, 2011
Clinical News

Vysis EGR1 FISH Probe Kit regulatory update

...FDA granted 510(k) clearance to Abbott's Vysis EGR1 FISH Probe Kit to aid in the prognosis...
...associated with an unfavorable prognosis in AML patients. Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Product: Vysis...
BioCentury | Sep 19, 2011
Product Development

Xalkori's footsteps

...variants, targets the EML4-ALK translocation. At the same time, FDA also approved the companion diagnostic Vysis...
BioCentury | Sep 5, 2011
Company News

Abbott, Pfizer sales and marketing update

...weeks in Xalkori's pivotal trials, the total treatment cost would be about $52,800-$76,800. The companion Vysis...
BioCentury | Aug 31, 2011
Company News

Pfizer, Abbott set price for Xalkori, companion test

...weeks in Xalkori's pivotal trials, the total treatment cost would be about $52,800-$76,800. The companion Vysis...
Items per page:
1 - 10 of 142